Summary
Pfizer Inc. has completed its previously announced debt exchange offers concerning notes originally issued by its recently acquired subsidiary, Hospira, Inc. The company successfully exchanged a significant portion of Hospira's outstanding notes for new notes issued by Pfizer. This action is a key step in integrating the Hospira debt structure into Pfizer's overall financial obligations, aiming to simplify its debt profile and potentially achieve more favorable terms. The exchange involved four series of Hospira notes maturing between 2017 and 2040. Concurrently, Pfizer solicited and obtained consents to amend the governing indentures of the Hospira notes. These amendments significantly reduce restrictive covenants, extend cure periods for defaults, and modify change of control provisions, aligning them with Pfizer's standard debt terms. This move is expected to streamline financial management and reduce administrative burdens associated with the acquired debt.
Key Highlights
- 1Pfizer completed debt exchange offers for Hospira Inc. notes on October 5, 2015.
- 2Substantial principal amounts of four series of Hospira notes (2017, 2020, 2023, 2040 maturities) were exchanged.
- 3Pfizer issued new notes in exchange for the tendered Hospira notes.
- 4Consents were obtained to amend the Hospira notes' indentures.
- 5Key amendments include elimination of most restrictive covenants and modification of default provisions.
- 6The exchange and amendments aim to integrate Hospira's debt and simplify Pfizer's financial structure.
- 7$80.5 million in Hospira notes remain outstanding after the exchange.